Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Abstract Text:

Allan Lipton,Richard J Cook,Pierre Major,Matthew R Smith,Robert E Coleman,Allan Lipton,Richard J Cook,Pierre Major,Matthew R Smith,Robert E Coleman,

OBJECTIVE: Most breast cancer patients with bone metastases will receive bisphosphonate treatment. This post hoc analysis investigated whether early normalization of urinary N-telopeptide of type I collagen (NTX) levels during bisphosphonate therapy correlates with a long-term reduction in skeletal-related event (SRE) risk and mortality in patients with breast cancer. METHODS: This was a retrospective subset analysis of a phase III randomized trial comparing i.v. zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma. Patients with breast cancer who had NTX assessments at baseline and at months 1 and 3 (n = 342) were classified as normal (NTX < 64 nmol/mmol creatinine) or elevated (NTX > or = 64 nmol/mmol creatinine). The relative risk for an SRE or death was estimated with Cox regression models. RESULTS: Among the 328 evaluable patients treated with zoledronic acid, 196 patients (59.7%) had elevated baseline NTX, with 149 of those patients (76.0%) having normalized NTX levels and 31 patients (15.8%) having persistently elevated NTX levels at 3 months. The normalized NTX group had significantly lower risks for a first SRE, a first fracture or surgery to bone, or death than the group that had persistently elevated NTX levels. CONCLUSIONS: These results suggest that early normalization of elevated baseline NTX while receiving zoledronic acid is associated with longer event-free and overall survival times compared with persistently elevated NTX. Further analyses in cancer patients with elevated marker levels are warranted to confirm the implications of these findings.

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Publishing Authors By Initials

A Lipton,RJ Cook,P Major,MR Smith,RE Coleman,A Lipton,RJ Cook,P Major,MR Smith,RE Coleman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The oncologist

VOLUME: 12

Page Numbers: 1035-43

Journal Abbreviation: Oncologist

ISSN: 1083-7159

DAY: 4

MONTH: Sep

YEAR: 2007

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9607837

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

AFFILIATION: Milton S. Hershey Medical Center, Penn State Cancer Institute, 500 University Drive, Hershey, Pennsylvania 17033, USA. alipton@psu.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Oncologist

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity Related Publications

• Ability to Exceed a Training Threshold During Tennis Activity in Persons with Physical Disabilities: 2279: Board #192 June 1 8:00 AM -9:30 AM.
• Accuracy, repeatability, and reproducibility of Artemis very high-frequency digital ultrasound arc-scan lateral dimension measurements.
• An increase in DNA double-strand breaks, induced by Ku70 depletion, is associated with human papillomavirus 16 episome loss and de novo viral integration events.
• Antigenicity of the Aeromonas salmonicida maltose-inducible outer membrane porin (maltoporin) and a hybrid protein derived from it.
• Clustering of hydatid infection in macropodids.
• Commentary: Is epidemiology really dead, anyway? A look back at Kenneth Rothman's 'The rise and fall of epidemiology, 1950-2000 AD'.
• DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
• Dissecting the molecular mechanisms of cancer through bioinformatics-based experimental approaches.
• Epirubicin for breast cancer during pregnancy: a case report.
• Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance.
• High-frequency ultrasonic imaging of the anterior segment using an annular array transducer.
• How do I fatten thee? Let me count the ways...
• Increased oxidative stress is associated with balanced increases in hepatocyte apoptosis and proliferation in glycerol-3-phosphate acyltransferase-1 deficient mice.
• Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
• Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
• Modification of the aerobic cytotoxicity of etanidazole.
• Molecular cloning and nucleotide sequence analysis of the maltose-inducible porin gene of Aeromonas salmonicida.
• Mutagenesis of rat acyl-CoA synthetase 4 indicates amino acids that contribute to fatty acid binding.
• NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration.
• Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75).
• Overexpression of rat long chain acyl-coa synthetase 1 alters fatty acid metabolism in rat primary hepatocytes.
• Precocious development of hydatid cysts in a macropodid host.
• Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
• Promoting bicycle helmet wearing by children using non-legislative interventions: systematic review and meta-analysis.
• Purification of immunoglobulins from chicken sera by thiophilic gel chromatography.
• Questioning specialists' attitudes to breast cancer follow-up in primary care.
• Recruitment and retention of children in longitudinal research.
• Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action.
• Treatment with 2-AAF blocks the small hepatocyte-like progenitor cell response in retrorsine-exposed rats.
• Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.